Recent advances in biological research on malignant glioma and their therapeutic relevance

Research output: Contribution to journalArticle

Abstract

Despite recent advances in various therapeutic modalities for treating malignant gliomas, these tumors are still hardly curable, and the development of the new therapies is warranted in the field of chemotherapy and radiotherapy. In this context, many therapeutic compounds have been investigated, and, especially, drug treatment using molecular targeting compounds has attracted considerable attention amongst neuro-oncologists. Since previous studies have elucidated that malignant gliomas show an up-regulation of various growth factor receptor-related activities, many clinical studies using compounds targeting those receptors have been conducted. However, the development of effective molecular targeting therapy for malignant gliomas is limited by a relative lack of understanding of the biology of glioma cells. Thus, laboratory investigation including an animal tumor model is indispensible in designing a better therapeutic approach for these tumors. On the other hand, genetic analysis of gliomas has led to the discovery of prognostic markers. Recent clinical studies focusing on genetic markers has revealed the importance of the methylation status of the O6-methylguanine-DNA methyltransferase promoter and mutational status of isocitrate dehydrogenase 1 as prognostic factors of gliomas, leading to the idea that genetic analysis could help in selecting cases with a favorable treatment response and, possibly, individualization of the treatment. In this text, recent advances in glioma biology are reviewed to help better understand the problems and future prospects in the treatment of these tumors.

Original languageEnglish
Pages (from-to)880-886
Number of pages7
JournalJapanese Journal of Neurosurgery
Volume19
Issue number12
DOIs
Publication statusPublished - 01-01-2010

Fingerprint

Glioma
Research
Therapeutics
Neoplasms
Isocitrate Dehydrogenase
Growth Factor Receptors
Methyltransferases
Genetic Markers
Methylation
Cell Biology
Up-Regulation
Radiotherapy
Animal Models
Drug Therapy
DNA
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

@article{afac7636079246b085ba049d0885bfaf,
title = "Recent advances in biological research on malignant glioma and their therapeutic relevance",
abstract = "Despite recent advances in various therapeutic modalities for treating malignant gliomas, these tumors are still hardly curable, and the development of the new therapies is warranted in the field of chemotherapy and radiotherapy. In this context, many therapeutic compounds have been investigated, and, especially, drug treatment using molecular targeting compounds has attracted considerable attention amongst neuro-oncologists. Since previous studies have elucidated that malignant gliomas show an up-regulation of various growth factor receptor-related activities, many clinical studies using compounds targeting those receptors have been conducted. However, the development of effective molecular targeting therapy for malignant gliomas is limited by a relative lack of understanding of the biology of glioma cells. Thus, laboratory investigation including an animal tumor model is indispensible in designing a better therapeutic approach for these tumors. On the other hand, genetic analysis of gliomas has led to the discovery of prognostic markers. Recent clinical studies focusing on genetic markers has revealed the importance of the methylation status of the O6-methylguanine-DNA methyltransferase promoter and mutational status of isocitrate dehydrogenase 1 as prognostic factors of gliomas, leading to the idea that genetic analysis could help in selecting cases with a favorable treatment response and, possibly, individualization of the treatment. In this text, recent advances in glioma biology are reviewed to help better understand the problems and future prospects in the treatment of these tumors.",
author = "Yuichi Hirose",
year = "2010",
month = "1",
day = "1",
doi = "10.7887/jcns.19.880",
language = "English",
volume = "19",
pages = "880--886",
journal = "Japanese Journal of Neurosurgery",
issn = "0917-950X",
publisher = "Japanese Congress of Neurological Surgeons",
number = "12",

}

Recent advances in biological research on malignant glioma and their therapeutic relevance. / Hirose, Yuichi.

In: Japanese Journal of Neurosurgery, Vol. 19, No. 12, 01.01.2010, p. 880-886.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recent advances in biological research on malignant glioma and their therapeutic relevance

AU - Hirose, Yuichi

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Despite recent advances in various therapeutic modalities for treating malignant gliomas, these tumors are still hardly curable, and the development of the new therapies is warranted in the field of chemotherapy and radiotherapy. In this context, many therapeutic compounds have been investigated, and, especially, drug treatment using molecular targeting compounds has attracted considerable attention amongst neuro-oncologists. Since previous studies have elucidated that malignant gliomas show an up-regulation of various growth factor receptor-related activities, many clinical studies using compounds targeting those receptors have been conducted. However, the development of effective molecular targeting therapy for malignant gliomas is limited by a relative lack of understanding of the biology of glioma cells. Thus, laboratory investigation including an animal tumor model is indispensible in designing a better therapeutic approach for these tumors. On the other hand, genetic analysis of gliomas has led to the discovery of prognostic markers. Recent clinical studies focusing on genetic markers has revealed the importance of the methylation status of the O6-methylguanine-DNA methyltransferase promoter and mutational status of isocitrate dehydrogenase 1 as prognostic factors of gliomas, leading to the idea that genetic analysis could help in selecting cases with a favorable treatment response and, possibly, individualization of the treatment. In this text, recent advances in glioma biology are reviewed to help better understand the problems and future prospects in the treatment of these tumors.

AB - Despite recent advances in various therapeutic modalities for treating malignant gliomas, these tumors are still hardly curable, and the development of the new therapies is warranted in the field of chemotherapy and radiotherapy. In this context, many therapeutic compounds have been investigated, and, especially, drug treatment using molecular targeting compounds has attracted considerable attention amongst neuro-oncologists. Since previous studies have elucidated that malignant gliomas show an up-regulation of various growth factor receptor-related activities, many clinical studies using compounds targeting those receptors have been conducted. However, the development of effective molecular targeting therapy for malignant gliomas is limited by a relative lack of understanding of the biology of glioma cells. Thus, laboratory investigation including an animal tumor model is indispensible in designing a better therapeutic approach for these tumors. On the other hand, genetic analysis of gliomas has led to the discovery of prognostic markers. Recent clinical studies focusing on genetic markers has revealed the importance of the methylation status of the O6-methylguanine-DNA methyltransferase promoter and mutational status of isocitrate dehydrogenase 1 as prognostic factors of gliomas, leading to the idea that genetic analysis could help in selecting cases with a favorable treatment response and, possibly, individualization of the treatment. In this text, recent advances in glioma biology are reviewed to help better understand the problems and future prospects in the treatment of these tumors.

UR - http://www.scopus.com/inward/record.url?scp=79951782105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951782105&partnerID=8YFLogxK

U2 - 10.7887/jcns.19.880

DO - 10.7887/jcns.19.880

M3 - Article

VL - 19

SP - 880

EP - 886

JO - Japanese Journal of Neurosurgery

JF - Japanese Journal of Neurosurgery

SN - 0917-950X

IS - 12

ER -